Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VRTX Stock Forecast 2026-2027
$441.20
Current Price
$112.22B
Market Cap
Buy 27
Hold 4
Sell 2
Wall St Analyst Ratings
Distance to VRTX Price Targets
+45.3%
To High Target of $641.00
+26.5%
To Median Target of $558.00
-25.2%
To Low Target of $330.00
VRTX Price Momentum
+0.3%
1 Week Change
-2.8%
1 Month Change
-9.8%
1 Year Change
-2.7%
Year-to-Date Change
-13.6%
From 52W High of $510.77
+21.7%
From 52W Low of $362.50
📊 TOP ANALYST CALLS
Did VRTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Vertex is one of their latest high-conviction picks.
Latest VRTX Stock Price Targets & Analyst Predictions
Based on our analysis of 47 Wall Street analysts, VRTX has a bullish consensus with a median price target of $558.00 (ranging from $330.00 to $641.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $441.20, the median forecast implies a 26.5% upside. This outlook is supported by 27 Buy, 4 Hold, and 2 Sell ratings.
The most optimistic forecast comes from Andrew S. Fein at HC Wainwright & Co., projecting a 45.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VRTX Analyst Ratings
27
Buy
4
Hold
2
Sell
VRTX Price Target Range
Low
$330.00
Average
$558.00
High
$641.00
Current: $441.20
Latest VRTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VRTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2026 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $612.00 |
| Mar 18, 2026 | Maxim Group | Naz Rahman | Buy | Upgrade | $575.00 |
| Mar 11, 2026 | Truist Securities | Joon Lee | Buy | Maintains | $525.00 |
| Mar 10, 2026 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $641.00 |
| Mar 10, 2026 | Citigroup | Geoff Meacham | Buy | Maintains | $585.00 |
| Mar 10, 2026 | B of A Securities | Ying Huang | Buy | Maintains | $598.00 |
| Mar 10, 2026 | Oppenheimer | Jay Olson | Outperform | Maintains | $600.00 |
| Mar 10, 2026 | Jefferies | Akash Tewari | Buy | Initiates | $580.00 |
| Mar 10, 2026 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $596.00 |
| Feb 17, 2026 | Canaccord Genuity | Whitney Ijem | Hold | Maintains | $441.00 |
| Feb 17, 2026 | Barclays | Eliana Merle | Overweight | Maintains | $607.00 |
| Feb 17, 2026 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $591.00 |
| Feb 13, 2026 | RBC Capital | Brian Abrahams | Outperform | Maintains | $541.00 |
| Feb 13, 2026 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $518.00 |
| Feb 13, 2026 | Oppenheimer | Jay Olson | Outperform | Upgrade | $540.00 |
| Feb 13, 2026 | Scotiabank | Greg Harrison | Sector Perform | Maintains | $558.00 |
| Feb 13, 2026 | Stifel | Paul Matteis | Hold | Maintains | $466.00 |
| Jan 28, 2026 | Barclays | Eliana Merle | Overweight | Upgrade | $606.00 |
| Jan 26, 2026 | UBS | Michael Yee | Buy | Maintains | $545.00 |
| Jan 23, 2026 | Evercore ISI Group | Liisa Bayko | Outperform | Maintains | $530.00 |
Vertex Pharmaceuticals Incorporated (VRTX) Competitors
The following stocks are similar to Vertex based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Vertex Pharmaceuticals Incorporated (VRTX) Financial Data
Vertex Pharmaceuticals Incorporated has a market capitalization of $112.22B with a P/E ratio of 28.8x. The company generates $12.00B in trailing twelve-month revenue with a 32.9% profit margin.
Revenue growth is +9.5% quarter-over-quarter, while maintaining an operating margin of +39.6% and return on equity of +22.5%.
Valuation Metrics
Market Cap
$112.22B
Enterprise Value
$107.51B
P/E Ratio
28.8x
PEG Ratio
0.9x
Price/Sales
9.4x
Growth & Margins
Revenue Growth (YoY)
+9.5%
Gross Margin
+85.4%
Operating Margin
+39.6%
Net Margin
+32.9%
EPS Growth
+30.5%
Financial Health
Cash/Price Ratio
+5.9%
Current Ratio
2.9x
Debt/Equity
10.9x
ROE
+22.5%
ROA
+12.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Vertex Pharmaceuticals Incorporated (VRTX) Business Model
About Vertex Pharmaceuticals Incorporated
What They Do
Biotechnology company focused on cystic fibrosis therapies.
Business Model
Vertex Pharmaceuticals generates revenue through the discovery, development, and commercialization of innovative therapies, primarily targeting cystic fibrosis. The company markets a range of treatments for CF patients, which includes TRIKAFTA/KAFTRIO and other therapies, positioning itself as a leader in addressing unmet medical needs in rare diseases.
Additional Information
Founded in 1989 and headquartered in Boston, Vertex has a significant financial presence with trailing twelve-month revenue of approximately $9.72 billion and a market capitalization of around $86-101 billion. The company's pipeline also explores treatments beyond cystic fibrosis, including potential therapies for acute and neuropathic pain.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
6,400
CEO
Dr. Reshma Kewalramani FASN, M.D.
Country
United States
IPO Year
1991
Website
www.vrtx.comVertex Pharmaceuticals Incorporated (VRTX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $441.2, representing a +1.27% change from its previous close.
Apr 17, 2026
By Zacks Equity Research
Tale of the Tape
Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $435.65, indicating a -1.37% shift from the previous trading day.
Apr 16, 2026
By Zacks Equity Research
Tale of the Tape
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know
Vertex Pharmaceuticals (VRTX) reached $436.16 at the closing of the latest trading day, reflecting a -2.38% change compared to its last close.
Apr 10, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Vertex Pharmaceuticals (VRTX) closed at $441.20, up 1.27% from the previous trading day.
Why It Matters
Vertex Pharmaceuticals' stock increase signals positive market sentiment, which could attract more buyers and influence future price movements and investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Vertex Pharmaceuticals is experiencing steady financial growth, while Mirum Pharmaceuticals is nearing profitability.
Why It Matters
Vertex's steady growth indicates strong performance and potential for continued returns. Mirum nearing profitability suggests improved financial health and investment viability.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Vertex Pharmaceuticals may face challenges from potential competitors in the cystic fibrosis market, but its core business appears stable in the near term.
Why It Matters
Vertex Pharmaceuticals faces competitive risks that could impact revenue, yet its established cystic fibrosis drugs remain secure, indicating potential stability in financial performance.
Source: The Motley Fool
Market Sentiment:
Neutral
Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade
3 days ago
Quick Summary
Vertex Pharmaceuticals (VRTX) closed at $435.65, down 1.37% from the previous trading day in the latest session.
Why It Matters
The decline in Vertex Pharmaceuticals' stock price may signal investor concerns about the company's performance or market conditions, potentially influencing trading decisions and portfolio adjustments.
Source: Zacks Investment Research
Market Sentiment:
Negative
Trump's Team Says Don't Worry About Rising Inflation. Here Are 3 Stocks to Buy If They're Wrong.
6 days ago
Quick Summary
NextEra Energy leads U.S. electric utilities, Vertex Pharmaceuticals focuses on cystic fibrosis therapies, and Walmart is the largest consumer staples firm with a strong e-commerce presence.
Why It Matters
NextEra Energy's size in utilities indicates stability; Vertex's niche in pharmaceuticals offers growth potential; Walmart's dominance in consumer staples and e-commerce suggests resilience and adaptability.
Source: The Motley Fool
Market Sentiment:
Positive
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
11 days ago
Quick Summary
Vertex (VRTX) is gaining attention from Zacks.com users, indicating potential interest and factors that may influence its stock performance.
Why It Matters
Increased attention from Zacks.com users signals heightened interest and potential volatility in Vertex's stock, which could influence investor sentiment and trading activity.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About VRTX Stock
What is Vertex Pharmaceuticals Incorporated's (VRTX) stock forecast for 2026?
Based on our analysis of 47 Wall Street analysts, Vertex Pharmaceuticals Incorporated (VRTX) has a median price target of $558.00. The highest price target is $641.00 and the lowest is $330.00.
Is VRTX stock a good investment in 2026?
According to current analyst ratings, VRTX has 27 Buy ratings, 4 Hold ratings, and 2 Sell ratings. The stock is currently trading at $441.20. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VRTX stock?
Wall Street analysts predict VRTX stock could reach $558.00 in the next 12 months. This represents a 26.5% increase from the current price of $441.20. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vertex Pharmaceuticals Incorporated's business model?
Vertex Pharmaceuticals generates revenue through the discovery, development, and commercialization of innovative therapies, primarily targeting cystic fibrosis. The company markets a range of treatments for CF patients, which includes TRIKAFTA/KAFTRIO and other therapies, positioning itself as a leader in addressing unmet medical needs in rare diseases.
What is the highest forecasted price for VRTX Vertex Pharmaceuticals Incorporated?
The highest price target for VRTX is $641.00 from Andrew S. Fein at HC Wainwright & Co., which represents a 45.3% increase from the current price of $441.20.
What is the lowest forecasted price for VRTX Vertex Pharmaceuticals Incorporated?
Price targets from Wall Street analysts for VRTX are not currently available. The stock is trading at $441.20.
What is the overall VRTX consensus from analysts for Vertex Pharmaceuticals Incorporated?
The overall analyst consensus for VRTX is bullish. Out of 47 Wall Street analysts, 27 rate it as Buy, 4 as Hold, and 2 as Sell, with a median price target of $558.00.
How accurate are VRTX stock price projections?
Stock price projections, including those for Vertex Pharmaceuticals Incorporated, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 4:14 AM UTC